Chronos Archive seal

Review checklist: Lili Boulanger (HR-ET025)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the exclusion of intestinal tuberculosis, the choice of risankizumab over an anti-TNF with an immunomodulator, the prednisone bridge, the vaccine plan, and the pregnancy counseling.
provenance reviewnot_startedDates, names, and the Prix de Rome from the Bibliothèque nationale de France authority record and reference biographies; the early-1915 symptoms from an encyclopedia article drawn from the Spycket biography; the intestinal tuberculosis and Crohn disease accounts graded R and disputed. Grove and the Fauser and Spycket works were not read directly. Her sister and mother appear only in documented claims.
safe messaging reviewnot_startedNo behavioral-health diagnosis; mild distress at diagnosis is screened and supported; death recorded without detail.

Judgment calls (dossier editorial resolutions)

  1. The historical diagnosis is not settled. Her chronic intestinal illness is described in reference works and essays as intestinal tuberculosis, and several give tuberculosis as the cause of death (sources 2, 3, 4, 6); later writers call it Crohn disease (sources 4, 5, 6, 7), a disease not described as a distinct entity until long after her death. No peer-reviewed article proposing either diagnosis was found (a PubMed search returned none), and no test from her lifetime is reported. Both are graded R with certainty disputed. The modern problem is linked to the documented early-1915 symptoms (D) and to both interpretations (R), with placement both_with_link. It is marked confirmed only because endoscopy, histology, imaging, and negative tuberculosis tests confirm it within the synthetic episode; this does not assert that she had Crohn disease. The synthetic workup deliberately excludes intestinal tuberculosis, the conflicting historical diagnosis, before any immunosuppression.
  2. Childhood pneumonia and immunity. Pneumonia at about two (1895) and frail health afterwards are documented (D). The usual account that it weakened her immune system is a biographical interpretation, graded R possible. One fetched source instead attributes her low immunity to inflammatory bowel disease.
  3. Names and places. The national library authority record gives the civil-register names Marie-Juliette Olga and death at Mézy-sur-Seine. One reference biography gives "Juliette Marie Olga" and death in Paris, and another gives "Julie-Marie Olga" and "the Paris area." The authority record is preferred, the alternatives are recorded in the claims, and the alias is Marie-Juliette Olga Boulanger.
  4. Sources not read. Grove Music Online, Annegret Fauser's work, and Jérôme Spycket's biography were not accessible. Spycket is used only as summarized in an encyclopedia article (source 5); claims resting on it alone are graded D with certainty probable. The Centre international Nadia et Lili Boulanger website could not be reached.
  5. Index age and whereabouts. The index visit on January 19, 2026 maps to January 19, 1915, when she was 21 and living in Paris, early in the year when headaches, loss of appetite, fever, and colitis-like symptoms are documented (source 5). The synthetic date of birth is August 21, 2004 (shift 111 years). The other visits (January 28, March 2, April 13, April 27, August 3, and October 19, 2026) map to the same days of 1915; the fetched sources place her in Paris in 1915 and say nothing of a journey that year, and no visit contradicts a documented event. Her 1914 travel to Rome and Nice falls before the index date. All visits fall within her lifetime.
  6. Choice of therapy. Decided: risankizumab, an interleukin-23 inhibitor, as early advanced therapy for moderate to severe ileocolonic disease (Montreal A2 L3 B1, SES-CD 14), with a short prednisone bridge. The alternatives (infliximab with azathioprine, adalimumab, ustekinumab, vedolizumab) were offered in the consultation. The reasons recorded: efficacy in ileocolonic disease, no need for an immunomodulator, a low rate of serious infection after tuberculosis had been excluded, and home injection that suits her work. The trade-off, recorded as hers to accept, is more limited pregnancy data than for anti-TNF drugs; the pregnancy counseling says the options will be reviewed before any planned pregnancy. The AGA 2021 guideline predates risankizumab's approval for Crohn disease; the ACG 2025 and ECCO 2024 guidelines and the label cover it.
  7. Tuberculosis exclusion. Negative interferon-gamma release assay, normal chest X-ray, small non-caseating granulomas, negative acid-fast stain and TB PCR, and a mycobacterial culture with no growth at five weeks and negative at six. The prednisone bridge and risankizumab began after the first results and before the final culture; the consultation records this as reasonable with the culture to be reviewed, and it was.
  8. Focused visits. The four chronic-care follow-ups (diagnosis, week 4, week 12, and six months) are documented as focused visits on the ACG 2025, AGA 2021, and ECCO 2024 Crohn disease guidelines, the ECCO infection guideline, the ACG preventive care guideline, STRIDE-II, and the risankizumab label (the CMID has no inflammatory bowel disease monograph). One protocol deviation is recorded: the hepatitis B surface antibody check due one to two months after the booster was left off the week-4 blood tests. It was drawn at week 12 (86 mIU/mL, protective), so no harm resulted, and the corrective action is recorded. The week-8 liver tests, drawn at the infusion center, are reported in prose and are not observations; so are the interferon-gamma release assay, the infection serologies, the stool tests, the mycobacterial culture, and the anti-HBs result, which are qualitative. The Harvey-Bradshaw Index and SES-CD have no LOINC code and are given in note text.
  9. Consultation. The inflammatory bowel disease referral and the consultation by Thaddeus Nwankwo-Delacroix, MD (a fictional consultant), on the day of the second visit, are S. The consultant answers the six referral questions with what the record shows happened afterwards: Crohn disease confirmed and tuberculosis excluded, with the culture reviewed; Montreal classification and high risk; risankizumab with a prednisone bridge; the vaccines, with no live vaccine needed; intravenous iron, vitamin D, calcium, a dietitian, and DXA; and treat-to-target monitoring, with pregnancy counseling.
  10. Sick visit. An unscheduled sick visit on April 13, 2026 (true frame April 13, 1915) for norovirus gastroenteritis ten weeks into risankizumab. It teaches the distinction between an infection and a Crohn flare, stool testing for Clostridioides difficile, and deferring calprotectin until recovery. It does not echo a documented illness.
  11. Preventive visit. An adult preventive visit (age 22, so `preventive_adult`) on October 19, 2026 (true frame October 19, 1915). Synthetic judgment calls: the HPV series in adolescence; the first cervical cytology at this visit, with no result; COVID-19 vaccination at a pharmacy, not recorded as given; advance care planning names no real person as her health care agent.
  12. Relatives and real people. Her sister appears only in documented claims (her dates and profession, the wartime committee, and dictation in her last illness); her mother does not appear. No relative, teacher, or companion is the source of any modern statement, decision, or health fact. The modern social history gives her a shared apartment and unnamed friends. The engagement mentioned in one source is not used.
  13. Family history. No family medical history is recorded; none is synthesized.
  14. Presenting concern. The intake documents list the presenting concern (PRB-002: abdominal pain, diarrhea, fevers, and weight loss) rather than Crohn disease, which is recorded from the diagnosis visit; the presenting concern is resolved, superseded by the diagnosis, from that visit on. Iron deficiency anemia and vitamin D deficiency resolve at week 12 and malnutrition at six months.
  15. Boulanger died in 1918, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-03-02
Progress note 03 (C-CDA)
Hepatitis B antibody after the boosterOne to two months after the doseNot drawn today, a deviation from the plan: it was left off the order with the infusion blood tests. Rescheduled with the week-12 tests. She has no known exposure and the booster was given, so harm is unlikely; standing orders for post-vaccine antibody checks are now added at the time of the dose

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-08-03
Progress note 06 (C-CDA)
ImagingIleocolonoscopy for endoscopic responseOrderedBooked in about two months

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0004The usual account is that the childhood pneumonia left her immune system weakened, so that she never fully recovered.possible
CLM-0009Her chronic intestinal illness has been described as intestinal tuberculosis, and several reference works give tuberculosis as the cause of her death.disputed
CLM-0010Later writers have proposed that her chronic intestinal illness was Crohn disease, which was not described as a distinct disease until well after her death.disputed

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-01-19Hemoglobin10.6 g/dL (low)Low
2026-01-19MCV76 fL (low)Low
2026-01-19Platelets452 10*3/uL (high)High
2026-01-19CRP38 mg/L (high)High
2026-01-19Fecal calprotectin1240 ug/g (high)High
2026-01-19Albumin3.3 g/dL (low)Low
2026-01-19Ferritin9 ng/mL (low)Low
2026-01-1925-hydroxyvitamin D18 ng/mL (low)Low
2026-03-02Hemoglobin11.6 g/dL (low)Low
2026-03-02CRP8 mg/L (high)High
2026-04-27Fecal calprotectin210 ug/g (high)High
2026-04-13CRP11 mg/L (high)High
2026-04-13Potassium3.4 mmol/L (low)Low